Ever Wish You Were Aware of a Hot New Sector Before It Experiences Explosive Growth?


New York, NY -- April 16, 2020 -- InvestorsHub NewsWire -- via Traders News Source -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies’ issues their latest research “The Next Hot Sector”

iBio, Inc. (NYSE: IBIO) has strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus. The stock has mostly rallied since it announced the partnership last month with Beijing CC-Pharming Ltd. The company is aiming to use its FastPharming facility, which was set up to create rapid delivery of medical countermeasures to treat a pandemic. The partnership aims to leverage CC-Pharming's work on Middle East respiratory syndrome, or MERS, another coronavirus, and iBio's manufacturing processes in plant-based expression systems.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is the leading developer of spider silk-based fibers. In recent news, the company says it has made strides toward year-round production of spider silk.  The Company also announced it has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. They plan to discuss this news in more detail through a webcast on March 19th.

See our full report READ MORE
Copy and paste to browser may be required https://www.industrynews.tips/

Inspyr Therapeutics, Inc. (OTC: NSPX) is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Mipsagargin is the Inspyr lead drug candidate and has been studied in a Phase 2 clinical trial in patients with Nexavar®-refractory hepatocellular carcinoma (HCC) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). Inspyr has strategically expanded its portfolio to include 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and Asia Pacific. Inspyr’s pipeline also includes the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases.

Galaxy Next Generation, Inc. (OTCQB: GAXY) is a provider of interactive learning technology solutions. Galaxy has received over $2.4 million in purchase orders and commitments for its interactive panels, intercom and audio technology solution products since the March announcement of the COVID-19 pandemic in the U.S. The company CEO stated: "While school closures would seem to be a negative for us given that 95% of our business is selling into the K-12 school market, it has actually proven to be beneficial to us. Most schools would wait until the summertime to implement new technologies into their classrooms. However, given the fact that most schools have completely closed for the remainder of the school year, we are seeing a huge influx of new orders."

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required –  https://www.industrynews.tips/

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
The sponsored and non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our report(s), disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source